MarketPeel
Insider Trading Intelligence
AM

Adam S. Mostafa

XFOR
CHIEF FINANCIAL OFFICER · X4 PHARMACEUTICALS, INC · CIK 0001738081
FILING MIX · LIFETIME35%/65%
BUYS
12
SELLS
22
TOTAL VALUE
$754.9K
COMPANIES
1
ACTIVE SINCE
Jun 2020
HOLDINGS NOW
850,000
AVG SELL PX
$1.01
TRADE KIND
SHOWING 34 / 34
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
21 backtested trades · 8 horizons · 2 pending
Forward-return performance of every backtestable P/S trade by Adam S. Mostafa, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d21+71.43%-1.58%+0.53%-2.11%-3.35%
14d21+66.67%-1.41%+0.99%-2.40%-4.45%
30d21+71.43%-2.20%+2.21%-4.41%-8.06%
60d21+61.90%-1.61%+4.10%-5.70%-8.51%
90d21+61.90%+0.41%+2.65%-2.24%-10.90%
180d21+80.95%-30.93%+7.48%-38.41%-45.30%
1y21+80.95%-29.57%+15.82%-45.39%-74.54%
2y21(2 pending)+100.00%-65.78%+32.80%-98.58%-99.40%
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
XFOR · 850,000 shares · as of Feb 12, 2025
0337,500675,0001,012,5001,350,00020212022202320242025SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
FLOW · 12 buys / 22 sellsCOVERAGE · 20 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
XFOR
X4 PHARMACEUTICALS, INC
PURCHASEGRANT
Stock grant
850,000850,000Feb 12, 2025Feb 14, 2025View →
XFOR
X4 PHARMACEUTICALS, INC
SALE
Chief Financial Officer
74,773$0.45$33.9K0Jan 24, 2025Jan 27, 2025View →
XFOR
X4 PHARMACEUTICALS, INC
PURCHASEGRANT
Stock grant
74,77374,773Jan 23, 2025Jan 27, 2025View →
XFOR
X4 PHARMACEUTICALS, INC
SALE
Chief Financial Officer
230,645$0.55$126.9K0Oct 7, 2024Oct 8, 2024View →
XFOR
X4 PHARMACEUTICALS, INC
PURCHASEGRANT
Stock grant
230,645230,645Oct 4, 2024Oct 8, 2024View →
XFOR
X4 PHARMACEUTICALS, INC
SALE
Chief Financial Officer
52,500$0.88$46.3K0Mar 11, 2024Mar 11, 2024View →
XFOR
X4 PHARMACEUTICALS, INC
PURCHASEGRANT
Stock grant
523,414523,414Feb 13, 2024Feb 16, 2024View →
XFOR
X4 PHARMACEUTICALS, INC
SALE
Chief Financial Officer
27,721$1.01$28.0K52,500Feb 12, 2024Feb 12, 2024View →
XFOR
X4 PHARMACEUTICALS, INC
SALE10b5-1
10b5-1 plan
230,645$0.73$168.4K80,221Nov 1, 2023Nov 3, 2023View →
XFOR
X4 PHARMACEUTICALS, INC
PURCHASEGRANT
Stock grant
230,645310,866Oct 31, 2023Nov 2, 2023View →
XFOR
X4 PHARMACEUTICALS, INC
SALE
Chief Financial Officer
2,641$1.89$5.0K80,221Jun 30, 2023Jul 5, 2023View →
XFOR
X4 PHARMACEUTICALS, INC
SALE
Chief Financial Officer
5,417$1.93$10.5K82,862Jun 23, 2023Jun 26, 2023View →
XFOR
X4 PHARMACEUTICALS, INC
SALE
Chief Financial Officer
5,417$2.22$12.0K88,279Jun 15, 2023Jun 16, 2023View →
XFOR
X4 PHARMACEUTICALS, INC
SALE
Chief Financial Officer
52,500$0.84$44.1K93,696Mar 10, 2023Mar 13, 2023View →
XFOR
X4 PHARMACEUTICALS, INC
SALE
Chief Financial Officer
27,721$0.93$25.8K146,196Feb 13, 2023Feb 15, 2023View →
XFOR
X4 PHARMACEUTICALS, INC
PURCHASEGRANT
Stock grant
1,350,0001,350,000Nov 7, 2022Nov 9, 2022View →
XFOR
X4 PHARMACEUTICALS, INC
SALE
Chief Financial Officer
10,834173,917Aug 17, 2022Aug 19, 2022View →
XFOR
X4 PHARMACEUTICALS, INC
SALE
Chief Financial Officer
2,641184,751Jun 30, 2022Jul 1, 2022View →
XFOR
X4 PHARMACEUTICALS, INC
SALE
Chief Financial Officer
5,416187,392Jun 24, 2022Jun 27, 2022View →
XFOR
X4 PHARMACEUTICALS, INC
SALE
Chief Financial Officer
5,416192,808Jun 16, 2022Jun 17, 2022View →
XFOR
X4 PHARMACEUTICALS, INC
PURCHASEGRANT
Stock grant
105,000198,224Mar 1, 2022Mar 1, 2022View →
XFOR
X4 PHARMACEUTICALS, INC
SALE
Chief Financial Officer
27,72193,224Feb 11, 2022Feb 14, 2022View →
XFOR
X4 PHARMACEUTICALS, INC
SALE
Chief Financial Officer
10,832$5.10$55.2K120,945Aug 17, 2021Aug 19, 2021View →
XFOR
X4 PHARMACEUTICALS, INC
SALE
Chief Financial Officer
2,641$6.64$17.5K131,777Jun 30, 2021Jul 1, 2021View →
XFOR
X4 PHARMACEUTICALS, INC
SALE
Chief Financial Officer
5,417$7.01$38.0K134,418Jun 24, 2021Jun 25, 2021View →
XFOR
X4 PHARMACEUTICALS, INC
PURCHASEGRANT
Stock grant
16,250139,835Jun 23, 2021Jun 25, 2021View →
XFOR
X4 PHARMACEUTICALS, INC
PURCHASEGRANT
Stock grant
16,250129,002Jun 15, 2021Jun 17, 2021View →
XFOR
X4 PHARMACEUTICALS, INC
SALE
Chief Financial Officer
5,417$7.84$42.5K123,585Jun 15, 2021Jun 17, 2021View →
XFOR
X4 PHARMACEUTICALS, INC
PURCHASEGRANT
Stock grant
83,163112,752Mar 24, 2021Mar 25, 2021View →
XFOR
X4 PHARMACEUTICALS, INC
SALE
Chief Financial Officer
10,834$7.08$76.7K29,589Sep 21, 2020Sep 22, 2020View →
XFOR
X4 PHARMACEUTICALS, INC
PURCHASEGRANT
Stock grant
16,25040,423Aug 17, 2020Aug 18, 2020View →
XFOR
X4 PHARMACEUTICALS, INC
PURCHASEGRANT
Stock grant
16,25024,173Aug 14, 2020Aug 18, 2020View →
XFOR
X4 PHARMACEUTICALS, INC
SALE
See Remarks
916$9.32$8.5K7,923Jun 30, 2020Jul 1, 2020View →
XFOR
X4 PHARMACEUTICALS, INC
SALE
See Remarks
1,725$9.04$15.6K8,839Jun 30, 2020Jul 1, 2020View →
Other insiders · XFOR
Loading peer insiders…
About this filer
CIK 0001738081
ROLE
Chief Financial Officer
PRIMARY
XFOR
COMPANIES
1
ACTIVE SINCE
Jun 2020
MARKETPEEL · /INSIDER/0001738081DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback